Renovare Environmental Inc Ordinary Shares RENO 深 沪
已收盘 06-16 16:00:00 美东时间
0.1721
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.1721
- 总市值 605.78万
- 52周最高 1.85
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.169
- 委 比 0.00%
- 总股本 3519.95万
- 历史最高 5.76
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.169
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多i-80 Gold Provides Progress Update on its New Development Plan
RENO, Nev., July 8, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80" or the "Company") is pleased to provide an update on the progress of its new development plan...
07-08 19:15
超长周期 多元“玩法”——石家庄消费市场年中大促观察
从5月13日到6月20日，史上最长的一个“618”促销活动已经临近尾声。记者观察到，今年的年中大促不仅来得更早，“玩法”也更加多元。从5月中旬开始，线下各大商...
06-16 09:06
AnaptysBio Reports Positive Phase 2b Trial Results
An announcement from AnaptysBio ( ($ANAB) ) is now available. On June 3, 2025, ...
06-04 05:51
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Renovaro Inc. subsidiary BioSymetrics receives a USPTO patent allowance for "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions." The patent enhances Renovaro's AI/ML IP portfolio by enabling integration and harmonization of diverse biomedical data sources into a standardized framework for predictive modeling. CEO David Weinstein highlights this as a strategic milestone, forming the foundation for an AI-powered drug ...
06-03 13:15
i-80 Gold Closes Previously Announced US$11 Million Private Placement
RENO, Nev., May 26, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE: IAUX) ("i-80" or the "Company") is pleased to announce that it has closed the previously announced concurrent privat...
05-26 18:03
i-80 Gold Closes US$173 Million Bought Deal Public Offering
RENO, Nev., May 16, 2025 /PRNewswire/ - i-80 Gold Corp. (TSX:IAU) (NYSE American:IAUX) ("i-80" or the "Company") is pleased to announce the closing of its previously announced bought deal pu...
05-16 21:25
晚期肾癌一线靶免联合治疗方案在华获批
来源：环球网 4月25日，辉瑞公司宣布其口服靶向药英立达®（通用名：阿昔替尼片）于2025年4月22日获得国家药品监督管理局（NMPA）批准，联合特瑞普利单抗...
04-27 15:33
辉瑞英立达获批国内首个且唯一晚期肾癌一线靶免联合治疗
经观健康 经济观察网讯 4月25日，辉瑞公司宣布，其口服靶向药英立达®（Inlyta®，通用名：阿昔替尼片）于2025年4月22日获得国家药品监督管理局（NM...
04-25 21:45
i-80 Gold Appoints New Chief Operating Officer
RENO, Nev., April 24, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE: IAUX) ("i-80 Gold", or the "Company") is pleased to announce the appointment of Paul Chawrun as Chief Operating Of...
04-24 18:00
道达尔润滑油子公司被罚：未依规对安全生产条件定期进行安全评价
转自：大众报业·齐鲁壹点 齐鲁晚报·齐鲁壹点 张頔 齐鲁晚报·齐鲁壹点记者于信用中国官方网站获悉，近日，道达尔润滑油（中国）旗下的道达尔（天津）工业有限公司收...
04-14 10:18
